Gornitzky represented the underwriters, led by Nomura and Roth Capital Partners, in RedHill Biopharma’s USD 40 million public offering of American Depository Shares (ADSs) on the NASDAQ Capital Market. RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on drugs for inflammatory and gastrointestinal diseases, is dually traded on the NASDAQ and the Tel Aviv Stock Exchange (NASDAQ: RDHL, TASE: RDHL).
Nomura Securities and Roth Capital Partners acted as joint book-running managers for the offering. MLV & Co. and H.C. Wainwright acted as co-managers for the offering.
The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Sagit Amit Evan.